右美托咪定在行无创通气治疗的重症哮喘患者中的疗效评价

Research on application of dexmedetomidine in noninvasive ventilation in treating severe asthma

目的探讨右美托咪定在行无创通气治疗的重症哮喘患者中的临床疗效。方法回顾性分析本院呼吸内科收治的79例重症哮喘患者的临床资料,按治疗方法将患者分为A组(常规药物)26例,B组(常规药物+无创正压通气)26例和C组(常规药物+右美托咪定联合无创正压通气)27例。观察3组患者哮喘缓解率、平均哮喘缓解时间、转换为有创机械通气率及误吸率。结果 C组患者哮喘缓解率、有创机械通气率、平均哮喘缓解时间均明显低于、短于A、B组,差异均有统计学意义(P<0.05);3组的误吸率无显著差异(P>0.05)。结论右美托咪定联合无创正压通气是治疗重症哮喘的有效方法,可明显提高哮喘缓解率、缩短哮喘缓解时间、避免有创机械通气带来的不良反应。

Objective To explore The clinical efficacy of the application of dexmedetomidine in noninvasive ventilation in treating severe asthma.Methods The medical records of the 79 patients,who were admitted to Department of pneumology due to severe asthma were analyzed retrospectively.The patients were divided into three groups in terms of the difference of therapies：conventional treatment group （A group） which involved 26 cases,conventional and noninvasive ventilation treatment group （B group） 26 cases,conventional,noninvasive ventilation and dexmedetomidine treatment group （C group） 27 cases.We observed the three groups in terms of records of asthma remission rate,the average time of asthma remission,rate of invasive mechanical ventilation and aspiration rate.Results Asthma remission rate,the average time of asthma remission,rate of invasive mechanical ventilation of group C were lower than groups A and B （P ＜ 0.05）.While aspiration rate of three groups was not statistically significant（P ＞0.05）.Conclusion Noninvasive ventilation and dexmedetomidine treatment is an effective treatment in treating severe asthma,which can improve the asthma remission rate,reduce the average time of asthma remission and avoid the side-effects of mechanical ventilation.